Legal Newsline

Sunday, August 18, 2019

DLA PIPER: DLA Piper advises Vivo Capital as lead investor in Series D financing for MacuLogix

By Press release submission | Apr 11, 2019

DLA Piper issued the following announcement on April 8.

DLA Piper represented Vivo Capital, LLC as the lead investor in US$38.7 million Series D financing for MacuLogix, Inc., a Harrisburg, Pennsylvania-based company providing eye care professionals with tools to diagnose and treat patients with age-related macular degeneration (AMD). Managing Director of Vivo Capital, Jack Nielsen and Nathan Dau, principal of Vivo Capital will both now join the MacuLogix Board of Directors.

Founded in 1996, Vivo Capital is a healthcare investment firm with more than US$3 billion under management that is focused on investing in and building high-quality companies in the US and abroad. Vivo Capital has offices in Palo Alto, Beijing, Shanghai and Taipei.

The DLA Piper team was led by partner Louis Lehot (Silicon Valley), co-chair of the US Emerging Growth and Venture Capital practice, and included associates Edmund Mokhtarian and Jonathan Luebbers (both of Silicon Valley).

Original source can be found here.

Want to get notified whenever we write about DLA Piper ?

Sign-up Next time we write about DLA Piper, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

DLA Piper

More News